FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W49200513> ?p ?o ?g. }

• W49200513 endingPage "4198" @default.
• W49200513 startingPage "4198" @default.
• W49200513 abstract "4198 Background: Previous studies suggested that chronic HCV infection may be more angiogenic than chronic HBV infection. In this study we sought to clarify if HCV- and HBV-related HCC may respond differently to thalidomide, an anti-angiogenic agent. Methods: One hundred and twelve patients with unresectable and non-embolizable HCC who had participated in 2 prospective clinical trials using single-agent thalidomide. The starting dose of thalidomide was 200 mg per day, and was gradually escalated in 100-mg steps if no limiting toxicities developed. Patients with positive serum HBV surface antigen (HBsAg) and negative anti-HCV antibody were categorized as HBV-related HCC (B-HCC, n=61), while patients with negative HBsAg and positive anti-HCV were categorized as HCV-related HCC (C-HCC, n=33). Response to thalidomide was defined by either (1) a complete or partial response according to WHO criteria or (2) a more than 50% decrease of serum α-fetoprotein level accompanied by clinically stable or improved condition lasting for more than 8 weeks for patients with elevated α-fetoprotein level. Results: All major clinicopathological features were comparable between the 2 groups except for age (C-HCC, 67.5 ± 7.6 years; B-HCC, 53.6 ± 13.7 years, p< 0.001). Eight patients with B-HCC and 9 patients with C-HCC responded to thalidomide treatment. The total response rate to thalidomide was 13.1% (95% C.I. 4.4 to 21.8%) for B-HCC and 27.3% (95% C.I. 11.2 to 43.3%) for C-HCC (p=0.09). Patients with C-HCC appeared to have better median time to disease progression (14.1 weeks vs. 8.3 weeks, p=0.03) and overall survival (32.6 weeks vs. 21.4 weeks, p=0.08) than patients with B-HCC. In multivariate analysis, staging (CLIP score), performance status and types of viral infection were independent predictors for overall survival (p<0.01), while only types of viral infection was independent predictor for time to disease progression (p=0.027). Conclusions: There is a trend favoring better anti-tumor activity of thalidomide in patients with HCV-related HCC. Whether this result is related to angiogenesis inhibition remains to be determined. No significant financial relationships to disclose." @default.
• W49200513 created "2016-06-24" @default.
• W49200513 creator A5008105414 @default.
• W49200513 creator A5013259882 @default.
• W49200513 creator A5023979525 @default.
• W49200513 creator A5051320042 @default.
• W49200513 creator A5081235717 @default.
• W49200513 creator A5084525824 @default.
• W49200513 date "2004-07-15" @default.
• W49200513 modified "2023-10-18" @default.
• W49200513 title "Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)- and hepatitis C (HCV)-related hepatocellular carcinoma (HCC)" @default.
• W49200513 doi "https://doi.org/10.1200/jco.2004.22.90140.4198" @default.
• W49200513 hasPublicationYear "2004" @default.
• W49200513 type Work @default.
• W49200513 sameAs 49200513 @default.
• W49200513 citedByCount "0" @default.
• W49200513 crossrefType "journal-article" @default.
• W49200513 hasAuthorship W49200513A5008105414 @default.
• W49200513 hasAuthorship W49200513A5013259882 @default.
• W49200513 hasAuthorship W49200513A5023979525 @default.
• W49200513 hasAuthorship W49200513A5051320042 @default.
• W49200513 hasAuthorship W49200513A5081235717 @default.
• W49200513 hasAuthorship W49200513A5084525824 @default.
• W49200513 hasConcept C126322002 @default.
• W49200513 hasConcept C203014093 @default.
• W49200513 hasConcept C2522874641 @default.
• W49200513 hasConcept C2776364478 @default.
• W49200513 hasConcept C2777382497 @default.
• W49200513 hasConcept C2777410769 @default.
• W49200513 hasConcept C2778019345 @default.
• W49200513 hasConcept C2779609412 @default.
• W49200513 hasConcept C2780593183 @default.
• W49200513 hasConcept C71924100 @default.
• W49200513 hasConcept C90924648 @default.
• W49200513 hasConceptScore W49200513C126322002 @default.
• W49200513 hasConceptScore W49200513C203014093 @default.
• W49200513 hasConceptScore W49200513C2522874641 @default.
• W49200513 hasConceptScore W49200513C2776364478 @default.
• W49200513 hasConceptScore W49200513C2777382497 @default.
• W49200513 hasConceptScore W49200513C2777410769 @default.
• W49200513 hasConceptScore W49200513C2778019345 @default.
• W49200513 hasConceptScore W49200513C2779609412 @default.
• W49200513 hasConceptScore W49200513C2780593183 @default.
• W49200513 hasConceptScore W49200513C71924100 @default.
• W49200513 hasConceptScore W49200513C90924648 @default.
• W49200513 hasIssue "14_suppl" @default.
• W49200513 hasLocation W492005131 @default.
• W49200513 hasOpenAccess W49200513 @default.
• W49200513 hasPrimaryLocation W492005131 @default.
• W49200513 hasRelatedWork W2002144368 @default.
• W49200513 hasRelatedWork W2061799564 @default.
• W49200513 hasRelatedWork W2065538639 @default.
• W49200513 hasRelatedWork W2089670318 @default.
• W49200513 hasRelatedWork W2095133085 @default.
• W49200513 hasRelatedWork W2369572641 @default.
• W49200513 hasRelatedWork W2900702767 @default.
• W49200513 hasRelatedWork W3031967535 @default.
• W49200513 hasRelatedWork W3112727549 @default.
• W49200513 hasRelatedWork W4323647428 @default.
• W49200513 hasVolume "22" @default.
• W49200513 isParatext "false" @default.
• W49200513 isRetracted "false" @default.
• W49200513 magId "49200513" @default.
• W49200513 workType "article" @default.